Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Lihua Song Ph.D. | Chairman of Board of Directors & President | -- | -- | 1957 |
Mr. Jian Ping Yao | Chief Executive Officer | -- | -- | 1972 |
Mr. Chenghao Hu | Financial Director | -- | -- | 1976 |
Mr. Hai Sheng | Senior Vice President | -- | -- | 1975 |
Ms. Hui Zhao | Senior VP & Director | -- | -- | 1974 |
Ms. Yuanyuan Zhou | VP & Director | -- | -- | 1972 |
Ms. Hongyi Yao | Vice President | -- | -- | 1972 |
Mr. Xueke Bao | Vice President | -- | -- | 1974 |
Mr. Yinghui Dou | Vice President | -- | -- | 1984 |
Mr. Tawei Chou | Vice President | -- | -- | 1985 |
Anhui Anke Biotechnology (Group) Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2,986
Description
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, and essential liquids; mouthwash; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits; paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab for the treatment of non-small cell lung cancer; and anti-PD1 for advanced cancers. The company was founded in 2000 and is based in Hefei, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
January 17, 2025 at 12:00 AM UTC
Ex-Dividend Date